Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of Botulinum Toxin Type A in Neurogenic OAB
NCT00876447Phase 3Completed
- Sponsor
- Allergan
- Start
- Jan 2009
- Primary completion
- Jun 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
A Phase 3 trial of onabotulinumtoxinA in neurogenic detrusor overactivity (NDO), sponsored by Allergan. Started Jan 2009; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT00876447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00876447.